GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
about
Apoptosis in pancreatic β-islet cells in Type 2 diabetesProbiotics and Prebiotics: Present Status and Future Perspectives on Metabolic DisordersIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseTranslational implications of the β-cell epigenome in diabetes mellitusPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseSimple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapyDual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands.Sitagliptin Improves the Impaired Acute Insulin Response during a Meal Tolerance Test in Japanese Patients with Type 2 Diabetes Mellitus: A Small-Scale Real-World Study.Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous systemEffect of endogenous GLP-1 on insulin secretion in type 2 diabetes.A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J miceAmbulatory treatment of type 2 diabetes in the U.S., 1997-2012.Alogliptin: a new addition to the class of DPP-4 inhibitors.Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States.Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice.Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitorThe regulation of appetite.Chylomicron formation and secretion is required for lipid-stimulated release of incretins GLP-1 and GIP.The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells.Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management.Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestionInternational Diabetes Federation guideline for management of postmeal glucose: a review of recommendationsThe effects of GLP-1 infusion in the hepatic portal region on food intake.Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.Alogliptin benzoate for the treatment of type 2 diabetes.DPP-4 inhibitors: focus on safety.Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.Theranostic magnetic resonance imaging of type 1 diabetes and pancreatic islet transplantation.New ways in which GLP-1 can regulate glucose homeostasis.Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice.Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.Taking aim at islet hormones with GLP-1: is insulin or glucagon the better target?Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide.GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
P2860
Q26747141-E90DF980-171A-46B1-AC33-419AD90643BAQ26752979-DF7B1549-4749-4DF3-B025-8469F182D4A8Q26827183-51DE9D33-CB3B-4ADB-A24E-0E996B513C7BQ27009451-2101B094-9FF9-434A-BEA1-1E0DB5A39C2DQ27027920-EEB4D0FB-380C-48C8-AFB6-CAEAB8FC250EQ28397980-E2E810C7-F53E-4840-89C4-C2B2E0811254Q30379845-E7180451-3128-449D-82F2-74F32B9455C2Q33785132-18355017-4FC9-46EE-930E-69974D45209BQ33840311-03304A94-39E4-47B6-B097-B9A1A4A9E18EQ33869732-CB86C3B6-C526-45F7-8783-79F66AB5BD55Q33913060-24AEE957-31E1-4FEA-9946-6BFEA147D0CEQ34170885-ECF1ADBE-547A-455C-9496-B73D5D7CAE23Q34259412-77880073-E96A-4039-83DE-7E3F776CAD40Q34620671-BD444E50-3BAC-456A-9627-41817CD56B9BQ34659509-CF6405BC-F990-4D74-B245-1EEA2D8F33F4Q34726493-C59E50F8-EA7A-46F4-A91B-2C7442844885Q34953338-85D9CA20-F168-48FA-8774-E52CDC7E8674Q35801801-11F44A1B-0F2A-41BE-8AC8-D9974A555821Q36095299-DB793E4C-1B66-4D3D-87AF-52577D23B53FQ36152785-EC139D29-4327-477B-8243-1E8162E50D21Q36423113-E8E8FCC0-D1EE-473A-AE98-87D35F270BB0Q36535937-4CBF551F-AE48-4CC8-9D31-CFCBBB376289Q36677839-B98B41A9-175C-467F-9839-97CEA2E3AC29Q36693199-622DA9F8-D78A-4E37-8A91-F515C9572E26Q36812821-383BA287-4AB0-49BF-8AB6-B4A34D822CC6Q36937820-32BEC192-2CC2-431C-87F8-955200F2964AQ37061286-7F5A2BEF-186E-464C-AA7A-4672EBA7D0C6Q37240511-537222E1-675B-4964-9435-A83C89AA443AQ37343491-C5094F1B-F472-4C51-8F01-C95DCE315ECBQ37375539-CB134331-6C0E-4F08-99EF-0D4FEB4F8F2BQ37980541-A3C7E0B1-63D4-4C79-B6C2-CD8F57D768F9Q38285608-44ABD677-A19B-45D2-A98C-30681258342CQ38403431-311463FE-F0B4-4AA8-A8E6-94E6DA0C2D5BQ39500260-DDEC359A-6674-422D-8103-FD7307716710Q40036350-125AE50B-E9ED-46A9-907A-8F8DB9CD03A8Q40237694-39CCCBE9-11AC-4D7E-A8A3-B532E62745A1Q40468370-9BB75923-0989-4E66-8DFF-4172B9D02AF7Q41279499-61994FD2-7198-4834-9F2E-D032C3D9A376Q41766825-740A8C2D-3324-42AF-94A8-ABB8F0F64B47Q41944168-257375F5-C01E-4FF1-9734-843B890C15BE
P2860
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
@ast
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
@en
type
label
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
@ast
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
@en
prefLabel
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
@ast
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
@en
P356
P1476
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
@en
P2093
P304
P356
10.1055/S-2004-826178
P50
P577
2004-11-01T00:00:00Z